BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33441719)

  • 21. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
    Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
    Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathologic correlates of
    Sethi TK; Kovach AE; Grover NS; Huang LC; Lee LA; Rubinstein SM; Wang Y; Morgan DS; Greer JP; Park SI; Ann Thompson-Arildsen M; Yenamandra A; Vnencak-Jones CL; Reddy NM
    Leuk Lymphoma; 2019 Dec; 60(12):2880-2889. PubMed ID: 31184237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma.
    Cho H; Kim SH; Kim SJ; Chang JH; Yang WI; Suh CO; Cheong JW; Kim YR; Lee JY; Jang JE; Kim Y; Min YH; Kim JS
    Ann Hematol; 2017 Jul; 96(7):1163-1173. PubMed ID: 28508176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ATP-binding cassette transporters in primary central nervous system lymphoma: decreased expression of MDR1 P-glycoprotein and breast cancer resistance protein in tumor capillary endothelial cells.
    Sakata S; Fujiwara M; Ohtsuka K; Kamma H; Nagane M; Sakamoto A; Fujioka Y
    Oncol Rep; 2011 Feb; 25(2):333-9. PubMed ID: 21165575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
    Ishikawa E; Nakamura M; Shimada K; Tanaka T; Satou A; Kohno K; Sakakibara A; Furukawa K; Yamamura T; Miyahara R; Nakamura S; Kato S; Fujishiro M
    J Gastroenterol; 2020 Jan; 55(1):39-50. PubMed ID: 31493237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.
    Braaten KM; Betensky RA; de Leval L; Okada Y; Hochberg FH; Louis DN; Harris NL; Batchelor TT
    Clin Cancer Res; 2003 Mar; 9(3):1063-9. PubMed ID: 12631608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and function of Siglec-15 in RLPS and its correlation with PD-L1: Bioinformatics Analysis and Clinicopathological Evidence.
    Cui L; Tian X; Yan L; Guan X; Dong B; Zhao M; Lv A; Liu D; Wu J; Hao C
    Int J Med Sci; 2022; 19(13):1977-1988. PubMed ID: 36438917
    [No Abstract]   [Full Text] [Related]  

  • 29. The significance of Siglec-15 expression in resectable non-small cell lung cancer.
    Hao JQ; Nong JY; Zhao D; Li HY; Su D; Zhou LJ; Dong YJ; Zhang C; Che NY; Zhang SC; Lin JZ; Yang JB; Zhang HT; Wang JH
    Neoplasma; 2020 Nov; 67(6):1214-1222. PubMed ID: 32749846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of hypoxia-inducible factor 1α, glucose transporter 1, and hexokinase 2 in primary central nervous system lymphoma and the correlation with the biological behaviors.
    Shen N; Wang Y; Sun X; Bai X; He J; Cui Q; Qian J; Zhu H; Chen Y; Xing R; Liu Q; Wu Y; Li J; Lai W; Sun S; Ji N; Liu Y
    Brain Behav; 2020 Aug; 10(8):e01718. PubMed ID: 32533646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of clinical characteristics and immunophenotypic biomarkers in 115 patients with primary central nervous system lymphoma.
    Chen BB; Xu XP; Shen L; Han TJ; Lin ZG; Chen Z; Kang H; Huang B; Lin GW
    Chin Med J (Engl); 2013 Feb; 126(3):482-7. PubMed ID: 23422111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis.
    Li B; Zhang B; Wang X; Zeng Z; Huang Z; Zhang L; Wei F; Ren X; Yang L
    Oncoimmunology; 2020 Aug; 9(1):1807291. PubMed ID: 32939323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy.
    Marcelis L; Antoranz A; Delsupehe AM; Biesemans P; Ferreiro JF; Debackere K; Vandenberghe P; Verhoef G; Gheysens O; Cattoretti G; Bosisio FM; Sagaert X; Dierickx D; Tousseyn T
    Cancer Immunol Immunother; 2020 Sep; 69(9):1751-1766. PubMed ID: 32335702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Tumor Microenvironment and Angiogenesis on Clinical Outcomes of Primary Central Nervous System Lymphoma.
    Wang HC; Hsiao HH; Du JS; Cho SF; Yeh TJ; Gau YC; Liu YC; Moi SH
    Biomed Res Int; 2021; 2021():3291762. PubMed ID: 34631879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
    Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
    Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1
    Pollari M; Brück O; Pellinen T; Vähämurto P; Karjalainen-Lindsberg ML; Mannisto S; Kallioniemi O; Kellokumpu-Lehtinen PL; Mustjoki S; Leivonen SK; Leppä S
    Haematologica; 2018 Nov; 103(11):1908-1914. PubMed ID: 30026337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
    Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
    Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the tumor microenvironment in primary central nervous system lymphoma: Implications for prognosis.
    Shi H; Sun X; Wu Y; Cui Q; Sun S; Ji N; Liu Y
    J Clin Neurosci; 2024 Jun; 124():36-46. PubMed ID: 38642434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
    Xing W; Dresser K; Zhang R; Evens AM; Yu H; Woda BA; Chen BJ
    Oncotarget; 2016 Sep; 7(37):59976-59986. PubMed ID: 27527850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic value of CD8
    Jin Q; Jiang H; Yue N; Zhang L; Li C; Dong C; Zeng P; Yue L; Wu C
    Leuk Lymphoma; 2024 Apr; 65(4):472-480. PubMed ID: 38198635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.